BACKGROUND: Uncertainty surrounds the safety and efficacy of pneumonectomy in the setting of induction chemoradiation for non-small cell lung cancer (NSCLC). We sought to evaluate fifteen years of experience with pneumonectomy with and without induction therapy. METHODS: Over a 15-year period [1999-2014], data were extracted from medical records of patients undergoing pneumonectomy for NSCLC. Primary outcomes were 5-year overall survival and mortality at 30, 60 and 90 days following operation. Morbidity data was also reviewed. Statistical comparisons were performed using the Chi-Square test. Kaplan-Meier curves were compared using the log rank test. Significance was defined as a P value less than 0.05. Patients with a prior cancer history, bilateral lung nodules and oligometastatic disease at presentation were excluded. RESULTS: After exclusion criteria were applied, 240 patients were analyzed and 137 (57%) underwent induction therapy prior to pneumonectomy. Five-year overall survival was 38.5%. Mortality at 90 days was 7.94%. There was no statistically significant difference in perioperative mortality with the addition of induction therapy. In fact, in the subset of patients with N2 disease (n=65), induction therapy was associated with improved 5-year overall survival (10.7% vs. 32.7%, P=0.014). Thirty-five percent of patients with N2 disease exhibited a complete response in the nodal basin following induction therapy; however, this did not confer a statistically significant overall or disease-free survival benefit. CONCLUSIONS: Pneumonectomy can safely be performed in the setting of induction chemoradiation. In patients with N2 disease, induction therapy may confer a survival benefit when the surgery can be done with limited morbidity and mortality.
BACKGROUND: Uncertainty surrounds the safety and efficacy of pneumonectomy in the setting of induction chemoradiation for non-small cell lung cancer (NSCLC). We sought to evaluate fifteen years of experience with pneumonectomy with and without induction therapy. METHODS: Over a 15-year period [1999-2014], data were extracted from medical records of patients undergoing pneumonectomy for NSCLC. Primary outcomes were 5-year overall survival and mortality at 30, 60 and 90 days following operation. Morbidity data was also reviewed. Statistical comparisons were performed using the Chi-Square test. Kaplan-Meier curves were compared using the log rank test. Significance was defined as a P value less than 0.05. Patients with a prior cancer history, bilateral lung nodules and oligometastatic disease at presentation were excluded. RESULTS: After exclusion criteria were applied, 240 patients were analyzed and 137 (57%) underwent induction therapy prior to pneumonectomy. Five-year overall survival was 38.5%. Mortality at 90 days was 7.94%. There was no statistically significant difference in perioperative mortality with the addition of induction therapy. In fact, in the subset of patients with N2 disease (n=65), induction therapy was associated with improved 5-year overall survival (10.7% vs. 32.7%, P=0.014). Thirty-five percent of patients with N2 disease exhibited a complete response in the nodal basin following induction therapy; however, this did not confer a statistically significant overall or disease-free survival benefit. CONCLUSIONS: Pneumonectomy can safely be performed in the setting of induction chemoradiation. In patients with N2 disease, induction therapy may confer a survival benefit when the surgery can be done with limited morbidity and mortality.
Authors: R Bueno; W G Richards; S J Swanson; M T Jaklitsch; J M Lukanich; S J Mentzer; D J Sugarbaker Journal: Ann Thorac Surg Date: 2000-12 Impact factor: 4.330
Authors: Robert James Cerfolio; Ayesha S Bryant; Virginia L Jones; Robert Michael Cerfolio Journal: Eur J Cardiothorac Surg Date: 2009-02-23 Impact factor: 4.191
Authors: Aaron M Allen; Steven J Mentzer; Beow Y Yeap; Ricardo Soto; Elizabeth H Baldini; Michael S Rabin; David J Sugarbaker; Raphael Bueno Journal: Cancer Date: 2008-03-01 Impact factor: 6.860
Authors: Anthony W Kim; L Penfield Faber; William H Warren; Sanjib Basu; Sean C Wightman; James A Weber; Philip Bonomi; Michael J Liptay Journal: Ann Thorac Surg Date: 2009-09 Impact factor: 4.330
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Stephen R Broderick; Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Daniel Morgansztern; Clifford G Robinson; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-09-26 Impact factor: 4.330
Authors: Mark J Krasna; Ziv Gamliel; Whitney M Burrows; Joshua R Sonett; King F Kwong; Martin J Edelman; Petr F Hausner; L Austin Doyle; Chad DeYoung; Mohan Suntharalingam Journal: Ann Thorac Surg Date: 2010-01 Impact factor: 4.330